

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT07422285

Status	RECRUITING
Phase	Phase 1
Sponsor	Amgen
Enrollment	400 participants

Key Eligibility Criteria

Inclusion (4)

- Male or female, of any race, between 18 and 60 years of age, inclusive.
- a. Females must not be pregnant or lactating.
- Body Mass Index (BMI) between 18.0 and 32.0 kg/m² inclusive.
- LDL-C level e 70 mg/dL (1.8 mmol/L) and d 190 mg/dL (4.9 mmol/L) at screening.

Exclusion (8)

- History or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator (or designee) would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
- History or current signs or symptoms of cardiovascular disease.
- History or evidence of clinically significant arrhythmia.
- History of hypersensitivity, intolerance, or allergy to evolocumab or its ingredients or other biological drugs.
- Uncontrolled hyperthyroidism or hypothyroidism.

... and 3 more (see full listing online)

Locations (4 total)

Fortrea Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States

QPS Bio-Kinetic, Springfield, Missouri, United States

Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States

... and 1 more locations